James P Allison
Overview
Explore the profile of James P Allison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
39119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sharma P, Allison J
Cancer Immunol Res
. 2023 Sep;
11(10):1298-1299.
PMID: 37702540
No abstract available.
12.
Baruch E, Nagarajan P, Gleber-Netto F, Rao X, Xie T, Akhter S, et al.
Res Sq
. 2023 Jul;
PMID: 37503252
While the nervous system has reciprocal interactions with both cancer and the immune system, little is known about the potential role of tumor associated nerves (TANs) in modulating anti-tumoral immunity....
13.
Sharma P, Goswami S, Raychaudhuri D, Siddiqui B, Singh P, Nagarajan A, et al.
Cell
. 2023 Apr;
186(8):1652-1669.
PMID: 37059068
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types...
14.
Cascone T, Leung C, Weissferdt A, Pataer A, Carter B, Godoy M, et al.
Nat Med
. 2023 Mar;
29(3):593-604.
PMID: 36928818
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of...
15.
Amaria R, Postow M, Burton E, Tetzlaff M, Ross M, Torres-Cabala C, et al.
Nature
. 2023 Mar;
615(7953):E23.
PMID: 36894629
No abstract available.
16.
Axelrod M, Meijers W, Screever E, Qin J, Carroll M, Sun X, et al.
Nature
. 2022 Nov;
611(7937):818-826.
PMID: 36385524
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The pathogenesis of ICI-associated myocarditis (ICI-MC) is...
17.
Zhou Y, Medik Y, Patel B, Zamler D, Chen S, Chapman T, et al.
J Exp Med
. 2022 Nov;
220(2).
PMID: 36367776
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by immune-related adverse events (irAEs). Limited understanding of irAE mechanisms hampers...
18.
Sharma P, Allison J
Sci Transl Med
. 2022 Nov;
14(670):eadf2947.
PMID: 36350993
Spatiotemporal immune monitoring in clinical trials and reverse translation will help to determine optimal combination immune therapies to cure cancer.
19.
Amaria R, Postow M, Burton E, Tetzlaff M, Ross M, Torres-Cabala C, et al.
Nature
. 2022 Oct;
611(7934):155-160.
PMID: 36289334
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma. We investigated this regimen in patients with resectable clinical stage III or oligometastatic...
20.
Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M, et al.
Cancer Cell
. 2022 May;
40(5):509-523.e6.
PMID: 35537412
Immune checkpoint blockade (ICB) therapy frequently induces immune-related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients...